AACR Special Conference: Targeting RAS
The American Association for Cancer Research (AACR) has made the difficult decision, after careful consideration and a comprehensive evaluation of currently available information related to the continuing situation with novel coronavirus (COVID-19) and the Omicron variant outbreak, to postpone the Targeting RAS Special Conference originally scheduled for January 7-10, 2022, in Lake Buena Vista, Florida. Please note that this postponement applies to this conference and does not apply to other planned AACR events.
We recognize that the new data, exchange of information, and opportunities for collaboration offered by this conference are highly valued by the cancer research community, and we are working to reschedule the conference as soon as possible. Information on the rescheduled program will be posted on www.aacr.org once it is available.
- If you submitted an abstract, please be advised that the abstracts that were submitted to the conference will not be published as originally scheduled. We encourage authors to submit an updated abstract once submission opens for the new conference dates. If you have any questions, please email [email protected].
- If you registered for the conference, the AACR will issue a refund in the manner in which it was received. If you have any questions, please contact [email protected].
- If you have a room reservation at Disney’s Yacht and Beach Club Resorts, your cancellation will be accepted at no charge five (5) days in advance of your scheduled check-in date; please contact the hotel at (407) 939-4686 to cancel your reservation as soon as possible.
- If you booked a flight to Orlando, many airlines have adjusted their rebooking and cancellation policies in response to the COVID-19 crisis. Please contact your airline or booking agent directly to cancel your travel to Orlando.
The AACR deeply appreciates your patience and understanding. Please look for emails in the coming weeks as we work to reschedule this program as soon as possible. If you have any questions, please email [email protected].
Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
Frank McCormick, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Deborah K. Morrison, National Cancer Institute, Frederick, Maryland
Mirati Therapeutics, Inc.
Reaction Biology Corp.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available